Investors might want to bet on Labcorp Holdings (LH) , as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of the most powerful forces impacting stock prices.A company's changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Consensus Estimate -- the consensus measure of EPS estimates from the sell-side analysts covering the stock -- for the current and following years.Since a changi ...

Investors might want to bet on Quest Diagnostics (DGX) , as it has been recently upgraded to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.A company's changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Consensus Estimate -- the consensus measure of EPS estimates from the sell-side analysts covering the stock -- for the current and following years.Since a cha ...

Financial Results Announcement - Labcorp Holdings Inc. will release its financial results for the second quarter of 2025 before the market opens on July 24, 2025 [1] - A conference call and webcast will be held at 9 a.m. ET on the same day to discuss the results [1] Webcast Details - The call will be available via live webcast on the Labcorp Investor Relations website, with registration required for dial-in access [2] - Participants are encouraged to join 10 minutes early, but can register and join at any time during the call [2] Replay Information - A replay of the webcast will be accessible approximately two hours after the live event and will remain available until July 11, 2026 [3] Company Overview - Labcorp is a global leader in laboratory services, aiding healthcare professionals and researchers in decision-making [4] - The company employs nearly 70,000 individuals and operates in approximately 100 countries, supporting over 75% of new drugs approved by the FDA in 2024 [4] - Labcorp conducts more than 700 million tests annually for patients worldwide [4]

Carrying a Zacks Rank #3 (Hold) at present, the laboratory service provider is concentrating more on areas that represent major growth opportunities and are expected to grow significantly faster than other therapeutic areas. It maintains a solid pipeline of potential acquisitions that fit its financial strategy and will enhance its organic growth. Additionally, the success of the LaunchPad initiative and a solid financial footing are highly encouraging for the company. Based in Burlington, NC, Labcorp offer ...

NeoGenomics (NEO) 2025 Conference June 04, 2025 02:00 PM ET Speaker0 Afternoon. I'm Tycho Peterson from the Life Science Tools Group. It's my pleasure to introduce our next company this afternoon, NeoGenomics. Tony, I'm going to maybe open it up with you. You've had a little bit of time in the CEO role here. Just talk about early learnings, how you're kind of thinking about stepping in, any big changes that need to happen? Speaker1 No. I think it's been a really good introductory period for me. I had the op ...

Core Insights - Labcorp has expanded its precision oncology portfolio with new test offerings for solid tumors and hematologic malignancies, along with enhanced biopharma solutions to accelerate clinical trials and companion diagnostic development [1][2] Diagnostics: New Solutions for Solid Tumor and Hematologic Malignancies - The company aims to improve patient access to testing and identify eligibility for targeted therapies through new diagnostic solutions [2] - New NGS panels for myeloid, lymphoid, and pan-heme indications provide broader genomic coverage and actionable insights for hematologic malignancies [4] - The launch of a Rapid AML Panel enhances testing for acute myeloid leukemia, enabling timely treatment decisions [4] - Expansion of OmniSeq® INSIGHT includes homologous recombination deficiency (HRD) testing to identify ovarian cancer patients likely to benefit from targeted therapies [4] - New FDA-approved companion diagnostics include HER2 categorization for breast cancer and the VENTANA® MET (SP44) RxDx Assay for non-squamous non-small cell lung cancer [4] Biopharma Laboratory Services: Accelerating Clinical Trials and Companion Diagnostic Development - Labcorp is enhancing global trial consistency and collaboration with biopharma customers [3] - The global expansion of Labcorp® Plasma Focus, a solid tumor liquid biopsy test, is now available in Geneva and Shanghai, complementing Labcorp Tissue® Complete for pan-solid tumors [4] - An enhanced digital pathology platform has been launched across global central labs, utilizing advanced scanning and image management systems for improved diagnostic insights [4] Company Overview - Labcorp is a global leader in laboratory services, supporting over 75% of new drugs approved by the FDA in 2024 and performing over 700 million tests annually [5]

Financial Data and Key Metrics Changes - The company reported revenues of $168 million for Q1 2025, an increase of 8% compared to the prior year, aligning with the previous guidance of 8% to 10% growth [24][29] - Adjusted EBITDA improved by 102% year-over-year to $7 million, marking the seventh consecutive quarter of positive adjusted EBITDA [24][10] - Total clinical revenue increased by $15 million or 11.3% in the quarter, while non-clinical revenue declined by $3.4 million or 15.8% [25][26] Business Line Data and Key Metrics Changes - Clinical testing volumes grew by 8% year-over-year, with NGS (Next Generation Sequencing) revenue growth of 18% [11][24] - Five new NGS products launched accounted for 22% of total clinical revenue in Q1 [11][12] - The company expects to achieve 25% annual growth in NGS, supported by an expanded sales force and upcoming product launches [12][13] Market Data and Key Metrics Changes - The NGS market is projected to grow at an annual rate of 10% to 15%, with the company aiming to grow above this rate [11] - The non-clinical business, which includes pharma, is expected to decline this year due to macroeconomic factors affecting R&D spending [15][27] Company Strategy and Development Direction - The company plans to focus on innovation through R&D, business development, and commercialization of new products to enhance patient care options [6][7] - The acquisition of Pathline is expected to accelerate growth and establish a local presence in the Northeast, contributing $12 million to $14 million in revenue for 2025 [8][29] - The company aims to leverage its strong position in community oncology and enhance its test offerings to drive incremental business [7][13] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the company's strong performance and the potential for growth in the community oncology market [36][40] - There are anticipated headwinds in the pharma sector, but clinical revenue growth is expected to offset these challenges [27][45] - The company is focused on integrating Pathline and optimizing operations to realize synergies in the second half of the year [29][30] Other Important Information - The company ended Q1 with cash and marketable securities of $358 million, a decrease of 7% year-over-year, and expects to maintain sufficient liquidity for investments [28][29] - The company is committed to increasing R&D investments to drive future product innovation [27][31] Q&A Session Summary Question: Can you discuss the last thirty days at the helm and any areas needing attention? - Management confirmed strong performance and positive interactions with the team, noting no surprises but areas for continued focus [36][39] Question: Can you unpack the NGS products driving clinical revenue? - Several new products contribute significantly, with a focus on community oncology, and investments in sales resources align with product launches [40][42] Question: What are the expectations for the pharma business this year? - The pharma segment is expected to decline similarly to last year, but clinical revenue growth will help offset this [45][46] Question: How will the Pathline acquisition impact revenue and integration? - Pathline is expected to contribute to revenue growth in the future, with integration efforts ongoing [29][30] Question: What is the timeline for the next-gen MRD product? - The timeline for the next-gen MRD product is set for 2026, with opportunities for acceleration through partnerships [66][67] Question: How will the sales force maturity impact revenue? - The sales force is expected to reach full productivity in 6 to 9 months, with leverage anticipated in the second half of the year [88][91]

1Q 2025 Financial Results Nasdaq: NEO 1 April 29, 2025 Safe Harbor Statements This presentation has been prepared by NeoGenomics, Inc. ("we," "us," "our," "NeoGenomics" or the "Company") and is made for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy securities, nor shall there be any sale of any securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securit ...

For the quarter ended March 2025, Labcorp (LH) reported revenue of $3.35 billion, up 5.3% over the same period last year. EPS came in at $3.84, compared to $3.68 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $3.41 billion, representing a surprise of -2.04%. The company delivered an EPS surprise of +2.95%, with the consensus EPS estimate being $3.73.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compa ...

NeoGenomics (NEO) Q1 2025 Earnings Call April 29, 2025 08:30 AM ET Company Participants Kendra Sweeney - Vice President of Investor Relations & CommunicationsTony Zook - CEOWarren Stone - President & COOAndrew Lukowiak - Chief Innovation OfficerJeffrey Sherman - Chief Financial OfficerDaniel Brennan - Managing DirectorMatthew Sykes - Financial AdvisorKareem Saad - Head of Strategy & TransformationMichael Ryskin - Managing DirectorAndrew Cooper - VP - Equity ResearchJack Melick - Equity Research AssociatePun ...